|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 4800 Deerwood Campus Parkway |
Address2 |
|
| City | Jacksonville |
State | FL |
Zip Code | 32246 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401103191-12
|
||||||||
|
6. House ID# 424860000
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Mai-Kim Norman |
Date | 10/20/2025 10:19:52 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues:
Same-day billing restrictions in Medicaid; Medicare Advantage & MA Rate Notice; Medicare/Transparency; Medicaid Cuts; Mental Health Care, Youth Mental Health; Site neutral payment reform; Health Equity Index reward factor; Health Equity Index for MA plans; MA Reform; Medicaid Provider Taxes
Bills:
H.R.5746 - Addressing Whole Health in Medicare Advantage Act (118th)
To amend title XVIII of the Social Security Act to expand the availability of supplemental benefits to certain Medicare Advantage enrollees.
Sponsor: Rep. Bilirakis, Gus M. [R-FL-12]
H.R. 7996, Improving CARE for Youth Act (118th)
To amend title XIX of the Social Security Act to ensure Medicaid coverage of mental health services and primary care services furnished on the same day.
Sponsor: Rep. Dunn, Neal P. [R-FL-2]
S.2556 - Improving CARE for Youth Act (118th)
To amend title XIX of the Social Security Act to ensure Medicaid coverage of mental health services and primary care services furnished on the same day.
Sponsor: Sen. Carper, Thomas R. [D-DE]
H.R.1 - One Big Beautiful Bill Act
This bill reduces taxes, reduces or increases spending for various federal programs, increases the statutory debt limit, and otherwise addresses agencies and programs throughout the federal government.
Sponsor: Rep. Arrington, Jodey C. [R-TX-19]
S.1105 - No UPCODE Act
To amend title XVIII of the Social Security Act to improve risk adjustment under Medicare Advantage.
Sponsor: Sen. Cassidy, Bill [R-LA]
H.R.2199 - Restore Protections for Dialysis Patients Act
To amend title XVIII of the Social Security Act to clarify and preserve the breadth of the protections under the Medicare Secondary Payer Act.
Sponsor: Rep. Kelly, Mike [R-PA-16]
S.1173 - Restore Protections for Dialysis Patients Act
To amend title XVIII of the Social Security Act to clarify and preserve the breadth of the protections under the Medicare Secondary Payer Act.
Sponsor: Sen. Cassidy, Bill [R-LA]
H.R.4077 - GUARD Veterans Health Care Act
To amend title 38, United States Code, and the Social Security Act to permit recovery from the Department of Veterans Affairs of costs from Medicare Advantage and Medicare prescription drug plans and to modify the authority for recovery by the United States of reasonable charges for certain care or services furnished to veterans for non-service-connected disabilities, and for other purposes.
Sponsor: Rep. Doggett, Lloyd [D-TX-37]
S.2145 - GUARD Veterans Health Care Act
To amend title 38, United States Code, and the Social Security Act to permit recovery from the Department of Veterans Affairs of costs from Medicare Advantage and Medicare prescription drug plans and to modify the authority for recovery by the United States of reasonable charges for certain care or services furnished to veterans for non-service-connected disabilities, and for other purposes.
Sponsor: Sen. Warren, Elizabeth [D-MA]
S.683 - More Behavioral Health Providers Act of 2025
To amend title XVIII of the Social Security Act to expand eligibility for incentives under the Medicare health professional shortage area bonus program to practitioners furnishing mental health and substance use disorder services.
Sponsor: Sen. Peters, Gary C. [D-MI]
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), White House Office, Executive Office of the President (EOP), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
Giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues:
340B Program/Transparency; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy
Bills:
S.1954 - Biosimilar Red Tape Elimination Act
To improve the requirements for making a determination of interchangeability of a biological product and its reference product.
Sponsor: Sen. Lee, Mike [R-UT]
S. 775, Increasing Transparency in Generic Drug Applications
To provide for increased transparency in generic drug applications.
Sponsor: Sen. Hassan, Margaret Wood [D-NH]
H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Sponsor: Rep. Dunn, Neal P. [R-FL-2]
S. 1067, Ensuring Timely Access to Generics Act (118th)
To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.
Sponsor: Sen. Shaheen, Jeanne [D-NH]
S.1041 - Affordable Prescriptions for Patients Act
A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes.
Sponsor: Sen. Cornyn, John [R-TX]
S.1040 - Drug Competition Enhancement Act
A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Sponsor: Sen. Cornyn, John [R-TX]
S.1096 - Preserve Access to Affordable Generics and Biosimilars Act
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Sponsor: Sen. Klobuchar, Amy [D-MN]
S.1095 - Stop STALLING Act
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Sponsor: Sen. Klobuchar, Amy [D-MN]
S.1097 - Interagency Patent Coordination and Improvement Act of 2025
To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.
Sponsor: Sen. Durbin, Richard J. [D-IL]
H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025
To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes.
Sponsor: Rep. Neguse, Joe [D-CO-2]
S.2658 - Medication Affordability and Patent Integrity Act
To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office.
Sponsor: Sen. Hassan, Margaret Wood [D-NH]
S.1302 - Increasing Transparency in Generic Drug Applications Act
To provide for increased transparency in generic drug applications.
Sponsor: Sen. Hassan, Margaret Wood [D-NH]
H.R.1843 - Increasing Transparency in Generic Drug Applications Act
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Sponsor: Rep. Dunn, Neal P. [R-FL-2]
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), White House Office, Labor - Dept of (DOL), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
tom |
giles |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |